FDA approves weight loss drug Zepbound to treat obstructive sleep apnea - KSUT
Zepbound, a weight loss drug by Eli Lilly & Co., is the first prescription medication approved by the FDA to treat obstructive sleep apnea (OSA) in adults with obesity. Studies show Zepbound, used with a reduced-calorie diet and exercise, significantly reduces OSA symptoms, including shallow breathing episodes. The approval reflects growing interest in weight loss drugs for conditions beyond obesity and diabetes.
Highlighted Terms
Related News
Zepbound, a weight loss drug by Eli Lilly & Co., is the first prescription medication approved by the FDA to treat obstructive sleep apnea (OSA) in adults with obesity. Studies show Zepbound, used with a reduced-calorie diet and exercise, significantly reduces OSA symptoms, including shallow breathing episodes. The approval reflects growing interest in weight loss drugs for conditions beyond obesity and diabetes.